9 results on '"Ross, Jonathan D. C."'
Search Results
2. Time to resolution of genital symptoms for uncomplicated gonorrhoea: a prospective cohort study.
- Author
-
Ayinde, Oluseyi and Ross, Jonathan D. C.
- Abstract
Objectives: To determine the time to resolution of symptoms (TTR) following treatment of uncomplicated gonorrhoea and to identify factors associated with TTR in a cohort of sexual health clinic attendees.Methods: Participants were recruited from 14 clinics across England into the 'Gentamicin for the Treatment of Gonorrhoea (GToG)' trial between October 2014 and November 2016. We analysed demographic, behavioural and clinical data in a subset of the GToG study cohort presenting with genital discharge and/or dysuria, who subsequently experienced microbiological clearance of Neisseria gonorrhoeae 2 weeks after treatment. Testing for gonorrhoea was performed using a nucleic acid amplification test. The results were expressed as median TTR (IQR) and HRs with 95% CIs for resolution of symptoms.Results: 216 participants (89% male) with a mean age of 32 years reported genital discharge (204/216 (94%)) or dysuria (173/216 (80%)) at their baseline visit. Symptom resolution occurred in 202/216 (94%) at the 2-week follow-up appointment. The median TTR was 2 days (IQR 1-3 days). 50/216 (23%) patients presented with gonorrhoea-chlamydia coinfection at their baseline attendance and in this group symptom resolution was slower (3 days for gonorrhoea-chlamydia coinfection compared with 2 days for gonorrhoea only, HR 0.68 (95% CI 0.48 to 0.95)). TTR was also longer in women (4 days for females compared with 2 days for males, HR 0.47 (95% CI 0.29 to 0.77)).Conclusions: The time to resolution of genital symptoms following effective treatment of gonorrhoea is variable, but 90% of patients report symptom resolution within 1 week. Concurrent chlamydia infection and being female were associated with prolonged TTR. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
3. Gentamicin, azithromycin and ceftriaxone in the treatment of gonorrhoea: the relationship between antibiotic MIC and clinical outcome.
- Author
-
Cole, Michelle J, Tan, Wei, Fifer, Helen, Brittain, Clare, Duley, Lelia, Hepburn, Trish, Lawrence, Tessa, Montgomery, Alan A, Sprange, Kirsty, Thandi, Sukhwinder, Churchward, Colin, Tripodo, Francesco, Woodford, Neil, and Ross, Jonathan D C
- Subjects
AZITHROMYCIN ,GONORRHEA ,CEFTRIAXONE ,GENTAMICIN ,NEISSERIA gonorrhoeae ,ANTIBIOTICS ,RANDOMIZED controlled trials ,RESEARCH ,RESEARCH methodology ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,NEISSERIA ,RESEARCH funding ,DRUG resistance in microorganisms ,STATISTICAL sampling ,MICROBIAL sensitivity tests - Abstract
Objectives: To investigate the relationship between MIC and clinical outcome in a randomized controlled trial that compared gentamicin 240 mg plus azithromycin 1 g with ceftriaxone 500 mg plus azithromycin 1 g. MIC analysis was performed on Neisseria gonorrhoeae isolates from all participants who were culture positive before they received treatment.Methods: Viable gonococcal cultures were available from 279 participants, of whom 145 received ceftriaxone/azithromycin and 134 received gentamicin/azithromycin. Four participants (6 isolates) and 14 participants (17 isolates) did not clear infection in the ceftriaxone/azithromycin and gentamicin/azithromycin arms, respectively. MICs were determined by Etest on GC agar base with 1% Vitox. The geometric mean MICs of azithromycin, ceftriaxone and gentamicin were compared using logistic and linear regression according to treatment received and N. gonorrhoeae clearance.Results: As the azithromycin MIC increased, gentamicin/azithromycin treatment was less effective than ceftriaxone/azithromycin at clearing N. gonorrhoeae. There was a higher geometric mean MIC of azithromycin for isolates from participants who had received gentamicin/azithromycin and did not clear infection compared with those who did clear infection [ratio 1.95 (95% CI 1.28-2.97)], but the use of categorical MIC breakpoints did not accurately predict the treatment response. The geometric mean MIC of azithromycin was higher in isolates from the pharynx compared with genital isolates.Conclusions: We found that categorical resistance to azithromycin or ceftriaxone in vitro, and higher gentamicin MICs in the absence of breakpoints, were poorly predictive of treatment failure. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
4. Acceptability of and treatment preferences for recurrent bacterial vaginosis—Topical lactic acid gel or oral metronidazole antibiotic: Qualitative findings from the VITA trial.
- Author
-
Anstey Watkins, Jocelyn, Ross, Jonathan D. C., Thandi, Sukhwinder, Brittain, Clare, Kai, Joe, and Griffiths, Frances
- Subjects
- *
BACTERIAL vaginitis , *DRUG resistance in bacteria , *ANTIBIOTICS , *DAPSONE , *LACTIC acid , *HUMAN sexuality , *DRUG efficacy , *MUPIROCIN - Abstract
Background: Bacterial vaginosis (BV) is associated with an elevated vaginal pH and the presence of abnormal offensive discharge. It is common, often recurrent, and the most effective treatment regimen is unknown. 'Metronidazole Versus lactic acId for Treating bacterial vAginosis' (VITA) is a UK-based randomised controlled trial assessing clinical and cost-effectiveness of topical lactic acid gel compared to oral metronidazole antibiotic for treating second and subsequent BV episodes. Few BV trials report on women's preferences for treatment in the context of their own experiences. Method: This qualitative study investigated the acceptability and tolerability of the two treatments. During the trial, semi-structured telephone interviews were undertaken between January—May 2018. A total of 33 women diagnosed with BV were consecutively sampled then interviewed from six sites across England. Thematic analysis was guided by the acceptability of health interventions framework. Potential causes of BV and its impact on women's lives were explored in addition to women's treatment preference and perceived treatment effectiveness. Results: Although women felt antibiotics treat BV effectively, and were associated with longer time periods between episodes, they generally preferred using the lactic acid gel because of ease of use, once daily application and less side-effects. Women would recommend the lactic acid gel to others for mild cases of BV but to take antibiotics when more severe. The risk of antibiotic drug resistance was a common concern. Self-help medicating or self-decision to not treat was also evident due to prior experience of poor outcomes from treatment. Triggers of BV were attributed to personal hygiene habits–soaps used to wash the vagina and sexual practices such as unprotected sex. Conclusion: Acceptability and preference for topical lactic acid gel or oral metronidazole tablets in the treatment of recurrent BV was affected by personal choice relating to affective attitude, burden, ethicality, intervention coherence, opportunity costs, and self-efficacy. These differed depending on ease of use, tolerability and past experiences, but not necessarily based on perceived drug effectiveness. Knowledge of a patient preference for topical lactic acid gel therapy despite lower perceived effectiveness may be useful for clinicians when making treatment decisions. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
5. Antibiotic therapy for pelvic inflammatory disease: an abridged version of a Cochrane systematic review and meta-analysis of randomised controlled trials.
- Author
-
Savaris, Ricardo F., Fuhrich, Daniele G., Duarte, Rui V., Franik, Sebastian, and Ross, Jonathan D. C.
- Subjects
AMINOGLYCOSIDES ,ANTIBIOTICS ,CEPHALOSPORINS ,CLINDAMYCIN ,METRONIDAZOLE ,AZITHROMYCIN ,DOXYCYCLINE ,QUINOLONE antibacterial agents ,CLINICAL trials ,COMPARATIVE studies ,RESEARCH methodology ,MEDICAL cooperation ,META-analysis ,PELVIC inflammatory disease ,RESEARCH ,SYSTEMATIC reviews ,EVALUATION research ,THERAPEUTICS - Abstract
Objective: To assess the effectiveness and safety of antibiotic regimens used to treat pelvic inflammatory disease (PID).Design: This is a systematic review and meta-analysis of randomised controlled trials (RCTs). Risk of bias was assessed using the criteria outlined in the Cochrane guidelines. Quality of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation.Data Sources: Eight electronic databases were searched from date of inception up to July 2016. Database searches were complemented by screening of reference lists of relevant studies, trial registers, conference proceeding abstracts and grey literature.Eligibility Criteria: RCTs comparing the use of antibiotics with placebo or other antibiotics for the treatment of PID in women of reproductive age, either as inpatient or outpatient treatment.Results: We included 37 RCTs (6348 women). The quality of evidence ranged from very low to high, the main limitations being serious risk of bias (due to poor reporting of study methods and lack of blinding), serious inconsistency and serious imprecision. There was no clear evidence of a difference in the rates of cure for mild-moderate or for severe PID for the comparisons of azithromycin versus doxycycline, quinolone versus cephalosporin, nitroimidazole versus no use of nitroimidazole, clindamycin plus aminoglycoside versus quinolone, or clindamycin plus aminoglycoside versus cephalosporin. No clear evidence of a difference between regimens in antibiotic-related adverse events leading to discontinuation of therapy was observed.Conclusions: We found no conclusive evidence that one regimen of antibiotics was safer or more effective than any other for the treatment of PID, and there was no clear evidence for the use of nitroimidazoles (metronidazole) compared with the use of other drugs with activity against anaerobes. More evidence is needed to assess treatments for women with PID, particularly comparing regimens with or without the addition of nitroimidazoles and the efficacy of azithromycin compared with doxycycline. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
6. Adverse effects of a single dose of gentamicin in adults: a systematic review.
- Author
-
Hayward, Rachel S., Harding, Jan, Molloy, Rob, Land, Lucy, Longcroft‐Neal, Kate, Moore, David, and Ross, Jonathan D. C.
- Subjects
GENTAMICIN ,DRUG side effects ,DRUG dosage ,TREATMENT of acute kidney failure ,MEDICAL protocols ,THERAPEUTICS - Abstract
Aims: To systematically review the frequency and type of adverse events associated with a single dose of intravenous or intramuscular gentamicin in adults, for any indication, in studies where a comparator was available. Methods: A review protocol was developed and registered (PROSPERO: CRD42013003229). Studies were eligible for review if they: recruited participants aged ≥16 years; used gentamicin intramuscularly or intravenously as a single one‐off dose; compared gentamicin to another medication or placebo; and monitored adverse events. MEDLINE, EMBASE, Cochrane Library, trial registries, conference proceedings and other relevant databases were searched up to November 2016. Risk of bias was assessed on all included studies. Results: In total, 15 522 records were identified. After removal of duplicates, screening of title/abstracts for relevance and independent selection of full texts by two reviewers, 36 studies were included. Across all the included studies, 24 107 participants received a single one‐off dose of gentamicin (doses ranged from 1 mg kg
–1 to 480 mg per dose). Acute kidney injury was described in 2520 participants receiving gentamicin. The large majority of cases were reversible. There were no cases of ototoxicity reported in patients receiving gentamicin. A meta‐analysis was not performed due to study heterogeneity. Conclusions: A significant number of patients saw a transient rise in creatinine after a single dose of gentamicin at doses up to 480 mg. Persistent renal impairment and other adverse events were relatively rare. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
7. Fluoroquinolone resistance in gonorrhoea: how, where and so what.
- Author
-
Ross, Jonathan D. C. and Ross, J D
- Subjects
GONORRHEA ,NEISSERIA infections ,QUINOLONE antibacterial agents ,DNA topoisomerases ,CHROMOSOME abnormalities ,GENETIC mutation - Abstract
The article discusses certain complications related to the use of fluoroquinolone antibiotics in treating patients with neisseria gonorrhoea. Fluoroquinolones inhibits the topoisomerase enzymes responsible for the maintenance of the gonococcal chromosome. Mutations in the DNA gyrase and topoisomerase IV enzymes result in resistance to fluoroquinolones. Reduced susceptibility to fluoroquinolones has become common but clinical resistance remains rare.
- Published
- 1998
- Full Text
- View/download PDF
8. Gentamicin versus ceftriaxone for the treatment of gonorrhoea (G-TOG trial): study protocol for a randomised trial.
- Author
-
Brittain, Clare, Childs, Margaret, Duley, Lelia, Harding, Jan, Hepburn, Trish, Meakin, Garry, Montgomery, Alan A, Tan, Wei, and Ross, Jonathan D C
- Subjects
GONORRHEA diagnosis ,ANTIBIOTICS ,COMBINATION drug therapy ,COMPARATIVE studies ,COST effectiveness ,DRUG resistance in microorganisms ,EXPERIMENTAL design ,GENTAMICIN ,GONORRHEA ,INTRAMUSCULAR injections ,RESEARCH methodology ,MEDICAL care costs ,MEDICAL cooperation ,MICROBIAL sensitivity tests ,ORAL drug administration ,RESEARCH ,STATISTICAL sampling ,TIME ,AZITHROMYCIN ,EVALUATION research ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,DISEASE remission ,CEFTRIAXONE - Abstract
Background: Gonorrhoea is a common sexually transmitted infection which causes genital pain and discomfort; in women it can also lead to pelvic inflammatory disease and infertility, and in men to epididymo-orchitis. Current treatment is with ceftriaxone, but there is increasing evidence of antimicrobial resistance which is reducing its effectiveness against gonorrhoea. A small, but increasing, number of patients have already been found to have highly resistant strains of gonorrhoea which has been associated with clinical failure. This trial aims to determine whether gentamicin is not clinically worse than ceftriaxone in the treatment of gonorrhoea.Methods/design: This is a blinded, two-arm, multicentre, noninferiority randomised trial. Patients are eligible if they are aged 16-70 years with a diagnosis of genital, pharyngeal and/or rectal gonorrhoea. Exclusion criteria are: known concurrent sexually transmitted infection(s) (excluding chlamydia); bacterial vaginosis and/or Trichomonas vaginalis infection; contraindications or an allergy to gentamicin, ceftriaxone, azithromycin or lidocaine; pregnancy or breastfeeding; complicated gonorrhoeal infection; weight under 40 kg; use of ceftriaxone, gentamicin or azithromycin within the preceding 28 days. Randomisation is to receive a single intramuscular injection of either gentamicin or ceftriaxone, all participants receive 1 g oral azithromycin as standard treatment. The estimated sample size is 720 participants (noninferiority limit 5%). The primary outcome is clearance of Neisseria gonorrhoeae at all infected sites by a negative Nucleic Acid Amplification Test, 2 weeks post treatment. Secondary outcomes include clinical resolution of symptoms, frequency of adverse events, tolerability of therapy, relationship between clinical effectiveness and antibiotic minimum inhibitory concentration for N. gonorrhoeae, and cost-effectiveness.Discussion: The options for future treatment of gonorrhoea are limited. Results from this randomised trial will demonstrate whether gentamicin is not clinically worse than ceftriaxone for the treatment of gonorrhoea. This will inform clinical practice and policy for the treatment of gonorrhoea when current therapy with cephalosporins is no longer effective, or is contraindicated.Trial Registration: International Standard Randomised Controlled Trial Number - ISRCTN51783227 , Registered on 18 September 2014. Current protocol version 2.0 17 June 2015. [ABSTRACT FROM AUTHOR]- Published
- 2016
9. How is gonorrhoea treated in genitourinary medicine clinics in the UK?
- Author
-
Ross, Jonathan D. C., Maw, Raymond, and Bacterial Special Interest Group, and the British Clinical Co-operative Group of the MSSVD
- Subjects
SOCIAL surveys ,SEXUALLY transmitted diseases ,CIPROFLOXACIN ,ANTIBIOTICS - Abstract
The article provides information on the survey of the way on how gonorrhoea will be treated in genitourinary medicine clinics in Great Britain. The survey found out that Ciprofloxacin is the most widely used antibiotic for the treatment of gonorrehea in GU clinics in even in regions where levels of resistances are above 5 percent.
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.